Guggenheim Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $29
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Seamus Fernandez has initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and a price target of $29.
August 08, 2023 | 9:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Apogee Therapeutics with a Buy rating and a price target of $29, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Guggenheim's Buy rating and price target of $29 for Apogee Therapeutics suggest a positive outlook for the stock, which could attract more investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100